- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1322KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 824KB)
Sotorasib – March 2022
Sotorasib: Tablet 120 mg; Lumakras®
Last updated
15 July 2022